Analyst: Illumina Shareholders Unlikely to Vote for Roche Offer, but Options Remain | GenomeWeb

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – As Illumina shareholders prepare for a vote that could determine the future of Roche's hostile bid for the San Diego company, an investment analyst today said that Roche is unlikely to make any headway in getting a deal done and only has a couple of other options.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.